Inventor
MURAKAMI MASATAKA
JP17 patents
⚠️ This page may combine multiple inventors who share the name “MURAKAMI MASATAKA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TAKEDA PHARMACEUTICALS CO
16 patentsUS10323026B2Jun 18, 2019
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO20 citations85
US10548899B2Feb 4, 2020
Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
TAKEDA PHARMACEUTICALS CO7 citations84
US10428056B2Oct 1, 2019
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO4 citations84
US10323027B2Jun 18, 2019
2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
TAKEDA PHARMACEUTICALS CO4 citations84
US9878989B2Jan 30, 2018
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO7 citations84
US10610520B2Apr 7, 2020
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO9 citations83
US10899752B2Jan 26, 2021
2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
TAKEDA PHARMACEUTICALS CO1 citations73
US10208046B2Feb 19, 2019
Nitrogen-containing heterocyclic compound
TAKEDA PHARMACEUTICALS CO4 citations73
US10807987B2Oct 20, 2020
Heterocyclic compound and use thereof
TAKEDA PHARMACEUTICALS CO5 citations72
US11236099B2Feb 1, 2022
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO4 citations71
US11274101B2Mar 15, 2022
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO1 citations62
US12378256B2Aug 5, 2025
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO0 citations61
US11702419B2Jul 18, 2023
Heterocyclic compound and use thereof
TAKEDA PHARMACEUTICALS CO1 citations61
US11834409B2Dec 5, 2023
Heterocyclic NMDA antagonists
TAKEDA PHARMACEUTICALS CO0 citations60
US12528802B2Jan 20, 2026
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO0 citations49
US11459325B2Oct 4, 2022
Heterocyclic compound
TAKEDA PHARMACEUTICALS CO0 citations49